ALK and non-small cell lung carcinoma: The KEYNOTE-024 [8] study investigated the efficacy of pembrolizumab compared to chemotherapy in previously untreated patients with metastatic NSCLC and PD-L1 ≥ 50%, but without EGFR and ALK mutations.